Abstract:There is a current medical need to identify innovative maintenance therapies to prevent allograft rejection in solid organ transplantation. During transplant rejection, recipient immune cells identify a grafted organ as foreign and attack it: CD4 + T cells orchestrate transplant rejection by recruiting a range of effector cells responsible for the damage of rejection including CD8 + T cells, NK cells, B cells and macrophages. These pathogenic immune cell responses can be driven by cytokines of the common gamma chain (γ c) cytokine family (IL2, IL4, IL7, IL9, IL15, and IL21). γ c cytokines signal through their corresponding receptors, expressed primarily on immune cells, that share a common coreceptor, interleukin 2 receptor subunit gamma (IL2RG) that is required for signaling. To understand the role of γ c cytokines in driving transplant rejection, we generated REGN7257, a fully human IL2RG monoclonal antibody that inhibits γ c cytokine-induced signaling, and we tested its ability to suppress allogeneic immune cell responses in a mouse model of skin graft rejection when delivered as a monotherapy and in combination with mycophenolate mofetil (MMF) or T cell costimulatory pathway blockers. In this model, recipient B6/129 (mixed background) Il2rg hu/hu mice were transplanted with tail skin from BALB/cJ donor mice. Graft survival was analyzed using a log rank Mantel-Cox test to detect statistically significant differences across groups (*=p<0.033; **= p<0.002; ***=p<0.0002; ****=p<0.0001). In a mouse model of skin graft rejection, γ c cytokine signaling blockade with REGN7257 given as maintenance immunosuppression effectively improved overall graft survival (Median Survival Time [MST] IL2RG=13) compared to mice that received a control antibody (MST CTRL=9 [****vs IL2RG Ab]), and with similar efficacy to that observed with the calcineurin inhibitor tacrolimus (MST TAC=12.5 [**vs control, n.s. vs IL2RG Ab]). In treatment combination experiments, while monotherapy treatment with the antiproliferative agent MMF was not as efficient as REGN7257 at delaying skin graft rejection (MST MMF=10 [*vs control] and MST IL2RG=12 [*vs MMF]), simultaneous blockade of cell proliferation and γ c cytokine signaling conferred an advantage over monotherapies (MST MMF+IL2RG=15.5 [****vs control, **vs IL2RG Ab]). Similarly, induction therapy consisting of γ c cytokine signaling blockade followed by maintenance immunosuppression using the CTLA4-Ig fusion protein abatacept, significantly improved overall skin graft survival (MST IL2RG+CTLA4=19.5 [****vs control]) compared to REGN7257 induction only (MST IL2RG=11 [****vs control and combo]) or abatacept maintenance only (MST CTLA4=10 [*vs control, ****vs combo]). Finally, maintenance immunosuppression combining blocking of γc cytokine signaling together with blocking of both CD28 and CD40L costimulatory signals prolonged skin graft survival better than any combination therapies of only 2 pathway blockers (MST TRIPLE=26 [**vs control] and MST DOUBLE=16-21 [n.s.-** vs triple]). Overall, our study showed that γ c cytokine blockade could potentially be an alternative to calcineurin inhibitor-based regimens to prevent rejection by specifically targeting immune cells. Our data also highlighted the inherent complexity of effector mechanisms and pathways involved in allograft rejection and showed that prolonged allograft survival requires simultaneous blockade of multiple T cell activating signals, including inhibition of cytokine signaling and costimulatory signals. These data provide evidence of γ c cytokines as key drivers of allogeneic immune cell responses during acute transplant rejection, offering a potentially novel strategy for the management of transplant patients.

BLOCK THE COMMON Γ CHAIN OF CYTOKINE RECEPTORS INDUCES PERMANENT ALLOGRAFT TOLERANCE

Efficacy of Ctla4-Ig in Preventing Acute Rejection of Fully Allogeneic Heart Allografts in Sensitized Recipients

A new approach to the blocking of alloreactive T cell-mediated graft-versus-host disease by in vivo administration of anti-CXCR3 neutralizing antibody.

REGULATORY T CELLS MAINTAIN PERIPHERAL TOLERANCE TO ISLET ALLOGRAFTS INDUCED BY INTRATHYMIC INJECTION OF MHC CLASS I ALLOPEPTIDES

Blockade of Common Gamma Chain Cytokine Signaling with REGN7257, an Interleukin 2 Receptor Gamma (IL2RG) Monoclonal Antibody, in Combination with Costimulatory Blockers Delayed Skin Graft Rejection in Mice

Short-term Pharmacological Inhibition of MyD88 Homodimerization by a Novel Inhibitor Promotes Robust Allograft Tolerance in Mouse Cardiac and Skin Transplantation.

Targeting Signal 1 Through Cd45rb Synergizes With Cd40 Ligand Blockade And Promotes Long Term Engraftment And Tolerance In Stringent Transplant Models

Anti-CD25 mAb, Anti-IL2 mAb, and IL2 Block Tolerance Induction Through Anti-CD154 mAb and Rapamycin in Xenogeneic Islet Transplantation

Mechanism of Induction of Transplant Tolerance Via Γc Signals Blockade in Murine Model

GITR Blockade Facilitates Treg Mediated Allograft Survival

Th1 cytokines, programmed cell death, and alloreactive T cell clone size in transplant tolerance.

Anti-γc and Anti-Il-2rβ Mabs Inhibit Donor-Antigen Reactive T Cells Proliferation and Induce H-Y Skin Graft Acceptance in Murine Model

Murine Islet Allograft Tolerance Upon Blockade of the B-Lymphocyte Stimulator, BLyS/BAFF

ADDITIVE EFFECTS OF ANTI-CD3 AND ANTI-CD28 ON PROLONGATION OF ALLOGENEIC SKINGRAFT SURVIVAL

Blockade of γc signals in combination with donor-specific transfusion induces cardiac allograft acceptance in murine models

Transfer of Regulatory T Cells Generated Ex Vivo Modifies Graft Rejection Through Induction of Tolerogenic CD4+CD25+ Cells in the Recipient

Anti-TCR Mab Induces Peripheral Tolerance to Alloantigens and Delays Islet Allograft Rejection in Autoimmune Diabetic NOD Mice.

Guiding Postablative Lymphocyte Reconstitution as a Route Toward Transplantation Tolerance

ALTERATIONS OF T CELL SIGNALING PATHWAYS IN ALLOGENEIC RAT HOSTS RENDERED TOLERANT BY ORAL ADMINISTRATION OF ALLOCHIMERIC CLASS I MHC PROTEINS

Prevention of Acute and Chronic Rejection of Rat Heart Allografts by Oral Administration of Tolerogenic Donor Recipient Allochimeric Class I Mhc Proteins

B-Cell Depletion Improves Islet Allograft Survival With Anti-Cd45rb